

**KIR2DL5B Antibody (Center) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP8909c****Specification**

---

**KIR2DL5B Antibody (Center) Blocking Peptide - Product Information**Primary Accession [Q8NHK3](#)**KIR2DL5B Antibody (Center) Blocking Peptide - Additional Information****Gene ID** 553128**Other Names**

Killer cell immunoglobulin-like receptor 2DL5B, CD158 antigen-like family member F2, Killer cell immunoglobulin-like receptor 2DLX, CD158f2, KIR2DL5B, CD158F, CD158F2, KIR2DL5, KIR2DLX

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP8909c](/products/AP8909c) was selected from the Center region of human KIR2DL5B. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**KIR2DL5B Antibody (Center) Blocking Peptide - Protein Information****Name** KIR2DL5B**Synonyms** CD158F, CD158F2, KIR2DL5, KIR2DLX**Function**

Receptor on natural killer (NK) cells for HLA-C alleles. Inhibits the activity of NK cells thus preventing cell lysis.

**Cellular Location**

Cell membrane; Single-pass type I membrane protein

**KIR2DL5B Antibody (Center) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

#### **KIR2DL5B Antibody (Center) Blocking Peptide - Images**

#### **KIR2DL5B Antibody (Center) Blocking Peptide - Background**

KIR2DL5B is a receptor on natural killer (NK) cells for HLA-C alleles. It inhibits the activity of NK cells thus preventing cell lysis.

#### **KIR2DL5B Antibody (Center) Blocking Peptide - References**

Gomez-Lozano N., et.al., Immunogenetics 54:314-319(2002).